Meeting
2013 ASCO Annual Meeting
Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis.
Authors
Sylvie Negrier
Léon-Bérard Cancer Centre, Lyon, France
Sylvie Negrier , Diane Charlotte Imbs , David Pérol , Ratislav Bahleda , Antoine Hollebecque , Helen Jane Boyle , Celine Ferlay , Severine Metzger , Ellen Blanc , Jean-Charles Soria , Bernard J. Escudier , Etienne Chatelut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01202032
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4574)
DOI
10.1200/jco.2013.31.15_suppl.4574
Abstract #
4574
Poster Bd #
32B
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh